Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
基本信息
- 批准号:7033212
- 负责人:
- 金额:$ 23.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-01-05 至 2010-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdenoviridaeRNA interferenceantineoplasticsapoptosisastrocytesathymic mousecell lineclinical researchcysteine endopeptidasesdrug resistancedrug screening /evaluationgliomahuman tissueimmunocytochemistryneoplasm /cancer chemotherapyneoplasm /cancer pharmacologynonhuman therapy evaluationreceptor expressionsurvivintissue /cell culturetransfection /expression vectortumor necrosis factor alphaxenotransplantation
项目摘要
DESCRIPTION (provided by applicant): Malignant gliomas are associated with high morbidity and mortality. Standard therapies such as surgery, radiation therapy and chemotherapy do not offer effective options and local recurrence is the norm. However, being locally malignant nonmetastatic tumors, they may be amenable to control using effective tumor-targeted local therapies. TNF- related apoptosis inducing ligand (TRAIL/Apo2L) induces apoptosis in gliomas in vitro and prolongs survival in xenograft rodent models. It is nontoxic to normal organs in animal models including primates. However, the efficacy of local intracranial delivery of TRAIL, its toxicity to brain-adjacent-to-tumor and selectivity towards gliomas in humans remain to be fully explored. In this study, we will test the efficacy and toxicity of TRAIL in a living human glioma & brain slice model and in xenograft models. Our preliminary data suggests that soluble TRAIL is active against gliomas in vitro and in vivo and that its activity is modulated by the Akt pathway. We hypothesize that: a) soluble untagged TRAIL will be effective against human glioma and nontoxic to normal brain 2) Inhibition of Akt can sensitize human gliomas to TRAIL and increase survival in a glioma model 3) resistance to TRAIL is mediated by differing mechanisms in normal and tumor cells permitting selective targeting of resistance mechanisms in tumors. To test these hypotheses, we propose the following specific aims 1) determine the efficacy and toxicity of soluble untagged TRAIL expressed by an adenovirus in a mouse intracranial xenograft and an ex-vivo living human glioma slice model. 2) determine the in vivo effect and relevance of Akt inhibition to TRAIL-induced apoptosis in gliomas. 3) determine the mechanisms of TRAIL resistance in normal brain and resistant glioma cells in human living tumor/ brain slice model and the effects of modulating these mechanisms on TRAIL sensitivity. The combined use of human living brain slices and intracranial xenograft models are aimed at providing direct and highly relevant data on the efficacy of TRAIL against human gliomas and its toxicity against the brain. The results of this study could also potentially provide a basis for clinical trials using TRAIL or analogues against gliomas and allow rational selection of agents to modulate the tumor resistance to TRAIL.
描述(由申请人提供):恶性神经胶质瘤与高发病率和死亡率相关。手术、放射治疗和化疗等标准疗法无法提供有效的选择,局部复发是常态。然而,由于它们是局部恶性非转移性肿瘤,因此可以使用有效的肿瘤靶向局部疗法来控制它们。 TNF 相关细胞凋亡诱导配体 (TRAIL/Apo2L) 可在体外诱导神经胶质瘤细胞凋亡,并延长异种移植啮齿动物模型的存活时间。它对动物模型(包括灵长类动物)的正常器官无毒。然而,TRAIL 局部颅内递送的功效、其对肿瘤邻近大脑的毒性以及对人类神经胶质瘤的选择性仍有待充分探索。在这项研究中,我们将在活体人类神经胶质瘤和脑切片模型以及异种移植模型中测试 TRAIL 的功效和毒性。我们的初步数据表明,可溶性 TRAIL 在体外和体内均具有抗神经胶质瘤活性,并且其活性受 Akt 途径调节。我们假设:a) 可溶性未标记的 TRAIL 将有效对抗人类神经胶质瘤,并且对正常大脑无毒 2) 抑制 Akt 可以使人类神经胶质瘤对 TRAIL 敏感并增加神经胶质瘤模型的存活率 3) 对 TRAIL 的耐药性是由正常细胞和肿瘤细胞中的不同机制介导的,从而允许选择性靶向肿瘤中的耐药机制。为了检验这些假设,我们提出以下具体目标1)确定腺病毒在小鼠颅内异种移植物和离体活人神经胶质瘤切片模型中表达的可溶性未标记TRAIL的功效和毒性。 2) 确定 Akt 抑制对 TRAIL 诱导的神经胶质瘤细胞凋亡的体内作用和相关性。 3)确定正常脑和人类活体肿瘤/脑切片模型中的耐药神经胶质瘤细胞的TRAIL抵抗机制以及调节这些机制对TRAIL敏感性的影响。人类活体脑切片和颅内异种移植模型的结合使用旨在提供有关 TRAIL 对人类神经胶质瘤的功效及其对大脑的毒性的直接且高度相关的数据。这项研究的结果还可能为使用 TRAIL 或类似物对抗神经胶质瘤的临床试验提供基础,并允许合理选择药物来调节肿瘤对 TRAIL 的耐药性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VINAY K PUDUVALLI其他文献
VINAY K PUDUVALLI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VINAY K PUDUVALLI', 18)}}的其他基金
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂
- 批准号:
10480888 - 财政年份:2019
- 资助金额:
$ 23.39万 - 项目类别:
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂
- 批准号:
10397791 - 财政年份:2019
- 资助金额:
$ 23.39万 - 项目类别:
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
一种新型 Hsp90 抑制剂作为成人胶质母细胞瘤的化疗和放射增敏剂
- 批准号:
10687871 - 财政年份:2019
- 资助金额:
$ 23.39万 - 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
- 批准号:
8731813 - 财政年份:2012
- 资助金额:
$ 23.39万 - 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
- 批准号:
8846550 - 财政年份:2012
- 资助金额:
$ 23.39万 - 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
- 批准号:
8459885 - 财政年份:2012
- 资助金额:
$ 23.39万 - 项目类别:
Patient Oriented Research Program in Neuro-oncology
以患者为中心的神经肿瘤学研究计划
- 批准号:
8300649 - 财政年份:2012
- 资助金额:
$ 23.39万 - 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
- 批准号:
7167160 - 财政年份:2006
- 资助金额:
$ 23.39万 - 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
- 批准号:
7340756 - 财政年份:2006
- 资助金额:
$ 23.39万 - 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
- 批准号:
7749939 - 财政年份:2006
- 资助金额:
$ 23.39万 - 项目类别:
相似海外基金
Investigation of improvement of skeletal muscle function by RNA interference for prevention of frailty
通过 RNA 干扰改善骨骼肌功能预防衰弱的研究
- 批准号:
23K10830 - 财政年份:2023
- 资助金额:
$ 23.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.
组织粘附 RNA 干扰纳米颗粒可阻止创伤后和自发性骨关节炎的进展。
- 批准号:
10539405 - 财政年份:2022
- 资助金额:
$ 23.39万 - 项目类别:
Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.
组织粘附 RNA 干扰纳米颗粒可阻止创伤后和自发性骨关节炎的进展。
- 批准号:
10688080 - 财政年份:2022
- 资助金额:
$ 23.39万 - 项目类别:
Using RNA interference to combat the worst emerging disease of wildlife
利用 RNA 干扰对抗野生动物最严重的新疾病
- 批准号:
DP220101361 - 财政年份:2022
- 资助金额:
$ 23.39万 - 项目类别:
Discovery Projects
RNA Interference and Heterochromatic Silencing in Replication and Quiescence
复制和静止过程中的 RNA 干扰和异染色质沉默
- 批准号:
10677770 - 财政年份:2022
- 资助金额:
$ 23.39万 - 项目类别:
Regulation of RNA interference pathways by extracellular cues
细胞外信号对 RNA 干扰途径的调节
- 批准号:
RGPIN-2019-04411 - 财政年份:2022
- 资助金额:
$ 23.39万 - 项目类别:
Discovery Grants Program - Individual
CAREER: Investigating the Role of an RNA Interference Pathway in Safeguarding the Tetrahymena Thermophila Somatic Genome
职业:研究 RNA 干扰途径在保护嗜热四膜虫体细胞基因组中的作用
- 批准号:
2143019 - 财政年份:2022
- 资助金额:
$ 23.39万 - 项目类别:
Continuing Grant
New Cancer Therapy: A Combination of RNA Interference and Gene Therapy
新的癌症疗法:RNA干扰和基因疗法的结合
- 批准号:
486535 - 财政年份:2022
- 资助金额:
$ 23.39万 - 项目类别:
Studentship Programs
RNA Interference and Heterochromatic Silencing in Replication and Quiescence
复制和静止过程中的 RNA 干扰和异染色质沉默
- 批准号:
10330828 - 财政年份:2022
- 资助金额:
$ 23.39万 - 项目类别:
CAREER: Abiotic degradation of emerging RNA interference pesticides
职业:新兴 RNA 干扰农药的非生物降解
- 批准号:
2046602 - 财政年份:2021
- 资助金额:
$ 23.39万 - 项目类别:
Continuing Grant